A phase 3, randomized study to evaluate the safety, tolerability, and immunogenicity of V116 in children and adolescents with increased risk of pneumococcal disease (STRIDE-13)

Human Vaccines & Immunotherapeutics 2026 Open access

Read full text
Authors: Vinita Jagannath, Jayani Pathirana, Carlos Alberto Pérez Yepes, Eduardo Lopez-Medina, Juan Andres Navarro, Piotr Korbal, Wanatpreeya Phongsamart, Ayano Inui, Anu Kantele, Jibran E. Atwi, B Tapiéro, Derya Alabaz
+9 more Fernando Baquero‐Artigao, Tiantian Zeng, D E Euler, Melanie Papa, Doreen A. Fernsler, Jun Park, Alejandra Esteves-Jaramillo, Heather Loryn Platt, the STRIDE-013 Study Group
DOI: 10.1080/21645515.2026.2684089
Cited by: 1
References: 25

Abstract

Pneumococcal disease (PD) causes significant illness and death, especially in young children, older adults, and individuals with chronic medical conditions. Due to increased risk, children with chronic conditions are often advised to receive additional pneumococcal vaccination beyond the routine primary series. This phase 3 study evaluated the safety and immunogenicity of V116, a 21-valent pneumococcal conjugate vaccine, compared to PPSV23 in children aged 2 to

Fields of Study & Subjects

Pneumonia and Respiratory Infections Respiratory viral infections research Influenza Virus Research Studies

Publication details

Journal / source
Human Vaccines & Immunotherapeutics
Publisher
Informa UK Limited
Volume
22
Issue
1
Pages
2684089–2684089
Publication date
23 June 2026
Language
EN